479 related articles for article (PubMed ID: 25462205)
1. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
[TBL] [Abstract][Full Text] [Related]
3. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
9. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
10. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer.
Dudek AZ; Leśniewski-Kmak K; Bliss RL; Brunstein C; Condon DL; Kratzke RA
Lung; 2005; 183(1):43-52. PubMed ID: 15793666
[TBL] [Abstract][Full Text] [Related]
11. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Chanpanitkitchot S; Tangjitgamol S; Khunnarong J; Thavaramara T; Pataradool K; Srijaipracharoen S
Asian Pac J Cancer Prev; 2014; 15(13):5215-21. PubMed ID: 25040977
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
